Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: In-vivo and in-vitro studies

Journal of Hypertension

Volumn 26, Issue 7, 2008, Pages 1435-1445

  Liu, Hao ^a   Kitazato, Keiko T ^a   Uno, Masaaki ^a   Yagi, Kenji ^a   Kanematsu, Yasuhisa ^a   Tamura, Tetsuya ^a   Tada, Yoshiteru ^a   Kinouchi, Tomoya ^a   Nagahiro, Shinji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiotensin II; Cerebral ischemia; Endothelium; Nitric oxide; Repair associated and growth associated proteins

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN II; CANDESARTAN; CANDESARTAN HEXETIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROMODULIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; ENOS PROTEIN, RAT; INDUCIBLE NITRIC OXIDE SYNTHASE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BIOAVAILABILITY; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL STIMULATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; TREATMENT OUTCOME; UMBILICUS; WISTAR RAT; ANIMAL; BIOSYNTHESIS; LIGATION; METABOLISM; MIDDLE CEREBRAL ARTERY; REPERFUSION INJURY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; LIGATION; MIDDLE CEREBRAL ARTERY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; TETRAZOLES; VASODILATION;

EID: 54449101078     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283013b6e     Document Type: Article

References (45)

1. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol 1987; 49:413-435.
2. Kagiyama T, Kagiyama S, Phillips MI. Expression of angiotensin type 1. and 2. receptors in brain after transient middle cerebral artery occlusion in rats. Regul Pept 2003; 110:241-247.
3. Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pept 1998; 783:1-11.
4. WaltherT, Olah L, Harms C, Maul B, Bader M, Hortnagl H, et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002; 16:169-176.
5. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT1. blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31.:2478-2486.
6. Bjorn D, Richard BD, Sverre EK, Stevo J, Gareth B, Ulf de F, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
7. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
8. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699-1703.
9. Plehm R, Barbosa ME, Bader M. Animal models for hypertension/blood pressure recording. Methods Mol Med 2006; 129:115-126.
10. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20:84-91.
11. Liu H, Uno M, Kitazato KT, Suzue A, Manabe S, Yamasaki H, et al. Peripheral oxidative biomarkers constitute a valuable indicator of the severity of oxidative brain damage in acute cerebral infarction. Brain Res 2004; 1025:43-50.
12. Bederson JB, Pitts LH, Germano SM, Nishimura M, Davis RL, Bartkowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986; 17:1304-1308.
13. Rodriguez J, Specian V, Maloney R, Jourd'heuil D, Feelisch M. Performance of diamino fluorophores for the localization of sources and targets of nitric oxide. Free Radic Biol Med 2005; 38:356-368.
14. Setsukinai K, Urano Y, Kakinuma K, Majima HJ, Nagano T. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 2003; 278:3170-3175.
15. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88:1474-1480.
16. 2regulated prolyl hydroxylation. Science 2001; 292:468-472.
17. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275.
18. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1. alpha in response to hypoxia is instantaneous. FASEB J 2001; 15:1312-1314.
19. Chavez JC, LaManna JC. Activation of hypoxia-inducible factor-1. in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1. J Neurosci 2002; 22:8922-8931.
20. Dawson DA, Hallenbeck JM. Acute focal ischemia-induced alterations in MAP-2. immunostaining: description of temporal changes and utilization as a marker for volumetric assessment of acute brain injury. J Cereb Blood Flow Metab 1996; 16:170-174.
21. Jacobson RD, Virag I, Skene JHP. A protein associated with axon growth, GAP43, is widely distributed and developmentally regulated in rat CNS. J Neurosci 1986; 6:1843-1855.
22. Baldin V, Lukas J, Marcotte MJ, Pagano M, Draetta G. Cyclin D1. is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7:812-821.
23. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. JClin Invest 2003; 111.:1201-1209.
24. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2005; 102:9056-9061.
25. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24:413-420.
26. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
27. Stead LG, Bellolio MF, Gilmore RM, Porter AB, Rabinstein AA. Pharmacologic elevation of blood pressure for acute brain ischemia. Neurocrit Care 2008; 8:259-261.
28. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, et al. Statin enhancement of collateralization in acute stroke. Neurology 2007; 68:2129-2131.
29. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, et al. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006; 24:535-539.
30. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21.:2175-2182.
31. Brdon J, Kaiser S, Hagemann F, Zhao Y, Culman J, Gohlke P. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke. J Hypertens 2007; 25:187-196.
32. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1. transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391-2398.
33. Yamakawa H, Jezova M, Ando H, Saavedra JM. Normalization ofendothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1. receptor inhibition. J Cereb Blood Flow Metab 2003; 23:371-380.
34. Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM. Negative regulation of RhoA/Rho kinase by angiotensin II type 2. receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 2005; 23:1037-1045.
35. Lu Q, Zhu YZ, Wong PT. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005; 16:1963-1967.
36. Yayama K, Hiyoshi H, Imazu D, Okamoto H. Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2. receptor. Hypertension 2006;48:958- 964.
37. Rabelink TJ, Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 2006; 26:267-271.
38. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998; 273:25804-25808.
39. Bevers LM, Braam B, Post JA, Zonneveld AJ, Rabelink TJ, Koomans HA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 2006; 47:87-94.
40. Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006; 98:453-462.
41. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2. receptor stimulation. Circulation 2004; 110:843-848.
42. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1. antagonist. Stroke 2002; 33:2297-2303.
43. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2. receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP- dependent protein kinase. J Hypertens 2006; 24:2417-2422.
44. Li Y, Jiang N, Powers C, Chopp M. Neuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1. immunoreactivity after focal cerebral ischemia in rats. Stroke 1998; 29:1972-1981.
45. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, et al. Angiotensin AT2. receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19:617-619.